


# CT CPT CODING GUIDE



# PET/CT CLINICAL APPLICATIONS

## ONCOLOGY

### BLADDER: 78815

- Determine extent of local, regional and distant disease

### BREAST: 78815

- Staging of Internal Mammary Nodes
- Exclude local recurrence of disease
- Evaluate response to treatment
- Accurately identify the extent of Metastatic Disease

### CERVICAL: 78815

- Staging of biopsy proven Cervical Cancer

### COLORECTAL: 78815

- Determine extent of regional and distant metastasis
- Evaluate for suspected recurrence in patients with serial rising CEA

### ESOPHAGEAL: 78815

- Determine the extent of local, regional and distant metastasis for initial staging and restaging
- Detection of squamous cell carcinoma of esophagus prior to surgical resection

### HEAD AND NECK: 78815

- Determine extent of local, regional and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy
- Assist in restaging post-surgical patients to determine recurrent/residual tumor

### LUNG: 78815

- Distinguish malignant from benign pulmonary nodules
- Staging of regional and/or distant metastasis
- Detect recurrent/residual tumor following completion of a planned course of treatment

### LYMPHOMA: 78815

- Determine extent of pretreatment disease
- Assess effectiveness of chemotherapy during the course of treatment
- Determine extent of disease following completion of a planned course of treatment

### MELANOMA: 78816

- Identify extent of distant disease spread in patients with high-risk melanoma or in suspected recurrence

### MYELOMA: 78815

- Determine extent of local, regional and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy

### OVARIAN: 78815

- Determine extent of local, regional and distant disease
- Detect recurrent/residual tumor following the completion of planned therapy

### PANCREAS: 78815

- Determine extent of local, regional and distant disease

### SMALL CELL LUNG: 78815

- Determine extent of local, regional and distant disease

### ALL SOLID TUMORS: 78815

- Determine extent of local, regional and distant disease

### STOMACH: 78815

- Determine extent of local, regional and distant disease

### THYROID: 78815

- Determine extent of local, regional and distant disease
- Detect metastatic or locally recurrent disease in patients post thyroidectomy or radioiodine ablation with elevated thyroglobulin and negative I-131 examination

### COMMON RADIATION TREATMENT PLANNING INDICATIONS

- Improve mapping of gross tumor volume for breast, head/neck and lung cancers

## MEDICARE ONCOLOGY GUIDELINES

### Initial Treatment Strategy (formerly diagnosis and initial staging)

- CMS covers one initial treatment strategy scan for all solid tumor types that are biopsy proven or strongly suspected based on other diagnostic testing.

### Now Covered for Initial Treatment Strategy:

- Brain, Breast, Cervical, Colorectal, Esophageal, Head & Neck (excluding CNS), NSC Lung, Small Cell Lung, Liver, Lymphoma, Melanoma, Myeloma, Ovarian, Pancreatic, Sarcoma, Testicular, and Distinct histological types of Thyroid Cancer

### Subsequent Treatment Strategy (formerly restaging and response to therapy)

- Restaging applies to testing after a course of treatment is completed.

### Now covered for Subsequent Treatment Strategy:

- Breast, Cervical, Colorectal, Esophageal, Head & Neck (excluding CNS), NSC Lung, Lymphoma, Melanoma, Ovarian, Distinct histological types of Thyroid Cancer
- All other malignancies are eligible for reimbursement through the National Oncologic PET Registry (NOPR) for Subsequent Treatment Strategy only.

## CARDIOLOGY

### MYOCARDIAL VIABILITY: 78459

- Determine the degree of viable myocardium prior to revascularization
- Aid in the pre-operative clinical evaluation of potential cardiac transplant cases

### MYOCARDIAL PERFUSION [N-13 Ammonia or Rb-82]:

- Identify ischemic disease

## NEUROLOGY

### DEMENCIA: 78608

- Differentiate Alzheimer's disease from fronto-temporal dementia

In patients with documented cognitive decline of at least six months and a recently established diagnosis of dementia who meet diagnostic criteria for both Alzheimer's disease (AD) and fronto-temporal dementia (FTD), who have been evaluated for specific alternate neurodegenerative diseases or causative factors, and for whom the cause of the clinical symptoms remains uncertain.

Additional conditions **MUST** be met. Please contact your service provider.

### EPILEPSY:

- Pre-surgical evaluation for the purpose of localization of a focus of refractory seizure activity

This information is not intended to replace or serve as a substitute for your duty to verify that such information is proper for your particular circumstance(s). In addition, due to the frequency that payer policies change, Alliance HealthCare Services may have a gap between publication and/or effective dates of posted changes and modifications to this document. Therefore, it is recommended that you always refer to the modified date noted within this document to determine current relevance. The information provided herein references coverage determinations set forth by The Centers for Medicare and Medicaid Services (CMS). We strongly recommend that you always check with your local Medicare carriers and payer criteria as coverage varies by region and plan. Not all insurance payers follow Medicare's coverage criteria for PET/CT services. Additional Medicare coverage documentation can be found online at [www.cms.hhs.gov/mcd/search.asp](http://www.cms.hhs.gov/mcd/search.asp).

CMS Documents cited: AB-01-168, AB-02-026, AB-02-065, AB-03-092, A-03-076, CMS-1471-FC, Transmittal 156, 278 and 290, CAG#00088R, Transmittal 31, change request 3741.

The health information contained herein is provided for educational purposes only and is not intended to be medical advice or to replace discussions with a health care professional.

© Copyright 2010 Alliance HealthCare Services. All rights reserved.

Revised 3/2010